Horizon Pharma PLC (HZNP) Given Average Recommendation of “Buy” by Brokerages

Share on StockTwits

Horizon Pharma PLC (NASDAQ:HZNP) has earned a consensus recommendation of “Buy” from the thirteen analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $19.20.

Several equities analysts recently weighed in on HZNP shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $22.00 target price on shares of Horizon Pharma in a research note on Thursday, March 1st. Cowen reaffirmed a “buy” rating and set a $24.00 target price on shares of Horizon Pharma in a research note on Thursday, March 1st. UBS Group set a $20.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Thursday, March 1st. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Wednesday, February 28th. Finally, Mizuho reaffirmed a “buy” rating and set a $18.00 target price on shares of Horizon Pharma in a research note on Monday, May 7th.

In other Horizon Pharma news, Chairman Timothy P. Walbert sold 83,353 shares of Horizon Pharma stock in a transaction on Friday, June 1st. The shares were sold at an average price of $16.17, for a total value of $1,347,818.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Brian K. Beeler sold 15,433 shares of Horizon Pharma stock in a transaction on Friday, June 8th. The stock was sold at an average price of $17.58, for a total transaction of $271,312.14. The disclosure for this sale can be found here. Insiders sold a total of 116,717 shares of company stock valued at $1,907,999 over the last three months. Corporate insiders own 3.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. Redwood Investments LLC boosted its stake in shares of Horizon Pharma by 43.9% during the 1st quarter. Redwood Investments LLC now owns 1,320,081 shares of the biopharmaceutical company’s stock worth $18,745,000 after purchasing an additional 402,610 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Horizon Pharma by 18.3% during the 1st quarter. Principal Financial Group Inc. now owns 555,534 shares of the biopharmaceutical company’s stock worth $7,889,000 after purchasing an additional 85,970 shares during the period. Foundry Partners LLC purchased a new position in shares of Horizon Pharma during the 1st quarter worth about $1,659,000. Millennium Management LLC boosted its stake in shares of Horizon Pharma by 299.2% during the 1st quarter. Millennium Management LLC now owns 1,124,465 shares of the biopharmaceutical company’s stock worth $15,967,000 after purchasing an additional 842,814 shares during the period. Finally, Point72 Asset Management L.P. boosted its stake in shares of Horizon Pharma by 252.2% during the 1st quarter. Point72 Asset Management L.P. now owns 1,312,900 shares of the biopharmaceutical company’s stock worth $18,643,000 after purchasing an additional 940,100 shares during the period. 84.96% of the stock is owned by hedge funds and other institutional investors.

Horizon Pharma traded up $0.12, hitting $17.69, during trading on Monday, according to Marketbeat.com. 67,832 shares of the company traded hands, compared to its average volume of 1,865,065. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 1.03 and a beta of 1.36. Horizon Pharma has a 1 year low of $10.13 and a 1 year high of $18.11. The company has a debt-to-equity ratio of 2.17, a quick ratio of 1.50 and a current ratio of 1.56.

Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Wednesday, May 9th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.11 by ($0.08). The company had revenue of $223.88 million for the quarter, compared to analysts’ expectations of $232.05 million. Horizon Pharma had a negative net margin of 45.06% and a positive return on equity of 16.97%. The business’s revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.21 earnings per share. equities research analysts forecast that Horizon Pharma will post 1.44 earnings per share for the current year.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply